CanSense-CRC Test
Early detection and triage of Colorectal Cancer (Bowel Cancer)
Development/ValidationActive
Key Facts
Indication
Early detection and triage of Colorectal Cancer (Bowel Cancer)
Phase
Development/Validation
Status
Active
Company
About CanSense
CanSense is pioneering a liquid biopsy for the early detection of colorectal cancer, a leading global cause of cancer mortality. Its core technology integrates high-throughput laser spectroscopy with proprietary AI analytics to create a simple, label-free blood test designed to triage patients for colonoscopy. The company aims to address a significant unmet need by improving early detection rates, reducing healthcare costs, and saving lives. CanSense is a private, pre-revenue company advancing its diagnostic toward clinical validation and commercialization.
View full company profile